关于睾丸生殖细胞肿瘤中MiR-371a-3p的研究进展
Research Progress on MiR-371a-3p in Testicular Germ Cell Tumors
DOI: 10.12677/ACM.2023.1371616, PDF,   
作者: 刘 盼：青海大学研究生院，青海 西宁；刘志波：青海红十字医院肿瘤内科，青海 西宁
关键词: 睾丸生殖细胞肿瘤；肿瘤标志物；MiR-371a-3p；Testicular Germ Cell Tumors； Tumor Markers； MiR-371a-3p
摘要: 睾丸生殖细胞肿瘤(TGCTs)来源于未分化的胚胎生殖细胞，在模仿胚胎和胚外发育阶段的同时保留胚胎生殖细胞的生物学和生化特征。在TGCTs的临床实践中有3种常用的经典肿瘤标志物，分别为甲胎蛋白、β人绒毛膜促性腺激素和乳酸脱氢酶，虽然这些肿瘤标志物在临床中常用于诊断、风险评估和确定患者病情，但是目前使用的生物标志物敏感性和特异性低于60%，不利于TGCTs的临床治疗。有研究指出循环microRNAs在TGCTs中有特异性，并可能满足临床需求。本文就TGCTs中miR-371a-3p的研究进展作一综述。
Abstract: Testicular germ cell tumors (TGCTs) are derived from undifferentiated embryonic germ cells that mimic embryonic and extraembryonic developmental stages while preserving the biological and biochemical characteristics of embryonic germ cells. In the clinical practice of TGCTs, there are three commonly used classical tumor markers, namely alpha-fetoprotein, β human chorionic gon-adotropin and lactate dehydrogenase, although these tumor markers are commonly used in clinical diagnosis, risk assessment and determination of patients’ conditions, but the sensitivity and speci-ficity of biomarkers currently used are less than 60%, which is not conducive to the clinical treat-ment of TGCTs. Circulating microRNAs have been shown to be specific in TGCTs and may meet clini-cal needs. This article reviews the research progress of miR-371a-3p in TGCTs.
文章引用：刘盼, 刘志波. 关于睾丸生殖细胞肿瘤中MiR-371a-3p的研究进展[J]. 临床医学进展, 2023, 13(7): 11555-11559. https://doi.org/10.12677/ACM.2023.1371616

参考文献

[1] 彭华红, 肖龙飞, 王林, 等. ARL4C在睾丸生殖细胞肿瘤中的表达及临床意义[J]. 天津医科大学学报, 2020, 26(3): 238-243.
[2] Katabathina, V.S., Vargas-Zapata, D., Monge, R.A., et al. (2021) Testicular Germ Cell Tumors: Classification, Pathologic Features, Imaging Findings, and Management. RadioGraphics, 41, 1698-1716. [Google Scholar] [CrossRef] [PubMed]
[3] Znaor, A., Skakkebaek, N.E., Rajpert-De Meyts, E., et al. (2020) Tes-ticular Cancer Incidence Predictions in Europe 2010-2035: A Rising Burden despite Population Ageing. International Journal of Cancer, 147, 820-828. [Google Scholar] [CrossRef] [PubMed]
[4] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[5] 李路, 李家贵. 原发性睾丸肿瘤研究新进展[J]. 现代泌尿生殖肿瘤杂志, 2009, 1(6): 321-324.
[6] Nettersheim, D. and Albers, P. (2022) Special Issue on Testis Cancer. World Journal of Urology, 40, 305-306. [Google Scholar] [CrossRef] [PubMed]
[7] Harries, L.W. (2019) RNA Biology Provides New Therapeutic Targets for Human Disease. Frontiers in Genetics, 10, Article No. 205. [Google Scholar] [CrossRef] [PubMed]
[8] Cortez, M.A., Bueso-Ramos, C., Ferdin, J., et al. (2011) Mi-croRNAs in Body Fluids—The Mix of Hormones and Biomarkers. Nature Reviews Clinical Oncology, 8, 467-477. [Google Scholar] [CrossRef] [PubMed]
[9] Zamore, P.D. and Haley, B. (2005) Ribo-Gnome: The Big World of Small RNAs. Science, 309, 1519-1524. [Google Scholar] [CrossRef] [PubMed]
[10] Hong, S.H., Kwon, J.T., Kim, J., et al. (2018) Profiling of Tes-tis-Specific Long Noncoding RNAs in Mice. BMC Genomics, 19, Article No. 539. [Google Scholar] [CrossRef] [PubMed]
[11] Eini, R., Dorssers, L.C. and Looijenga, L.H. (2013) Role of Stem Cell Proteins and microRNAs in Embryogenesis and Germ Cell Cancer. The International Journal of Developmental Bi-ology, 57, 319-332. [Google Scholar] [CrossRef] [PubMed]
[12] Syring, I., Bartels, J., Holdenrieder, S., et al. (2015) Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR- 372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer. Journal of Urology, 193, 331-337. [Google Scholar] [CrossRef] [PubMed]
[13] Belge, G., Hennig, F., Dumlupinar, C., et al. (2020) Graded Ex-pression of microRNA-371a-3p in Tumor Tissues, Contralateral Testes, and in Serum of Patients with Testicular Germ Cell Tumor. Oncotarget, 11, 1462-1473. [Google Scholar] [CrossRef] [PubMed]
[14] Spiekermann, M., Belge, G., Winter, N., et al. (2015) MicroRNA miR-371a-3p in Serum of Patients with Germ Cell Tumours: Evaluations for Establishing a Serum Biomarker. Andrology, 3, 78-84. [Google Scholar] [CrossRef] [PubMed]
[15] Vilela-Salgueiro, B., Barros-Silva, D., Lobo, J., et al. (2018) Germ Cell Tumour Subtypes Display Differential Expression of microRNA371a-3p. Philosophical Transactions of the Royal Society B: Biological Sciences, 373, Article ID: 20170338. [Google Scholar] [CrossRef] [PubMed]
[16] Salvatori, D.C.F., Dorssers, L.C.J., Gillis, A.J.M., et al. (2018) The microRNA-371 Family as Plasma Biomarkers for Monitoring Undifferentiated and Potentially Malignant Human Plu-ripotent Stem Cells in Teratoma Assays. Stem Cell Reports, 11, 1493-1505. [Google Scholar] [CrossRef] [PubMed]
[17] Dieckmann, K.P., Radtke, A., Spiekermann, M., et al. (2017) Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. European Urology, 71, 213-220. [Google Scholar] [CrossRef] [PubMed]
[18] Palmer, R.D., Murray, M.J., Saini, H.K., et al. (2010) Malignant Germ Cell Tumors Display Common microRNA Profiles Resulting in Global Changes in Expression of Messenger RNA Targets. Cancer Research, 70, 2911-2923. [Google Scholar] [CrossRef] 
[19] Belge, G., Dieckmann, K.P., Spiekermann, M., et al. (2012) Serum Levels of microRNAs miR-371-3: A Novel Class of Serum Biomarkers for Testicular Germ Cell Tumors? Euro-pean Urology, 61, 1068-1069. [Google Scholar] [CrossRef] [PubMed]
[20] Dieckmann, K.P., Spiekermann, M., Balks, T., et al. (2012) Mi-croRNAs miR-371-3 in Serum as Diagnostic Tools in the Management of Testicular Germ Cell Tumours. British Journal of Cancer, 107, 1754-1760. [Google Scholar] [CrossRef] [PubMed]
[21] Bezan, A., Gerger, A. and Pichler, M. (2014) MicroRNAs in Testicular Cancer: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy. AntiCancer Research, 34, 2709-2713.
[22] Sanders, I., Holdenrieder, S., Walgenbach-Brünagel, G., et al. (2012) Evaluation of Reference Genes for the Analysis of Serum miRNA in Patients with Prostate Cancer, Bladder Cancer and Renal Cell Carcinoma. Interna-tional Journal of Urology, 19, 1017-1025. [Google Scholar] [CrossRef] [PubMed]
[23] Gillis, A.J., Stoop, H.J., Hersmus, R., et al. (2007) High-Throughput microRNAome Analysis in Human Germ Cell Tumours. The Journal of Pathology, 213, 319-328. [Google Scholar] [CrossRef] [PubMed]
[24] Bing, Z., Master, S.R., Tobias, J.W., et al. (2012) MicroRNA Expression Profiles of Seminoma from Paraffin-Embedded Formalin-Fixed Tissue. Virchows Ar-chiv, 461, 663-668. [Google Scholar] [CrossRef] [PubMed]
[25] Lobo, J., Gillis, A.J.M., Jerónimo, C., et al. (2019) Human Germ Cell Tumors Are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. In-ternational Journal of Molecular Sciences, 20, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[26] Mego, M., van Agthoven, T., Gronesova, P., et al. (2019) Clinical Util-ity of Plasma miR-371a-3p in Germ Cell Tumors. Journal of Cellular and Molecular Medicine, 23, 1128-1136. [Google Scholar] [CrossRef] [PubMed]
[27] Badia, R.R., Abe, D., Wong, D., et al. (2021) Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. Journal of Urology, 205, 137-144. [Google Scholar] [CrossRef] 
[28] Bagrodia, A., Savelyeva, A., Lafin, J.T., et al. (2021) Impact of Circulating microRNA Test (miRNA-371a-3p) on Appropriateness of Treatment and Cost Outcomes in Patients with Stage I Non-Seminomatous Germ Cell Tumours. BJU International, 128, 57-64. [Google Scholar] [CrossRef] [PubMed]
[29] Charytonowicz, D., Aubrey, H., Bell, C., et al. (2019) Cost Analysis of Noninvasive Blood-Based microRNA Testing versus CT Scans for Follow-Up in Patients with Testicular Germ-Cell Tumors. Clinical Genitourinary Cancer, 17, e733-e744. [Google Scholar] [CrossRef] [PubMed]
[30] van Ag-thoven, T., Eijkenboom, W.M.H. and Looijenga, L.H.J. (2017) microRNA-371a-3p as Informative Biomarker for the Follow-Up of Testicular Germ Cell Cancer Patients. Cellular Oncology (Dordr), 40, 379-388. [Google Scholar] [CrossRef] [PubMed]
[31] Gilligan, T.D., Seidenfeld, J., Basch, E.M., et al. (2010) American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors. Journal of Clinical Oncology, 28, 3388-3404. [Google Scholar] [CrossRef] 
[32] Ehrlich, Y., Beck, S.D., Foster, R.S., et al. (2013) Serum Tumor Markers in Testicular Cancer. Urologic Oncology, 31, 17-23. [Google Scholar] [CrossRef] [PubMed]

为你推荐